Aim Bulletin
Evgen agrees fresh licensing deal with Spanish institutions
Clinical-stage drug development company Evgen Pharma announced a memorandum of understanding with the University of Seville, Consejo Superior de Investigaciones Científicas (CSIC) and Fundación Pública Andaluza Progreso y Salud on behalf of the Institute of Biomedicine of Seville on Tuesday, for second-generation sulforaphane analogues.
Ten Lifestyle wins new multi-year contract in Japan
Concierge platform operator Ten Lifestyle Group has won a contract with one of Japan's largest wealth management businesses, it announced on Tuesday.
Revenue, profit and cash well above expectations at Blancco
Data erasure and mobile technology company Blancco said in a trading update on Tuesday that, following the “significant” growth experienced in the second half of the last financial year, it had continued to benefit from growth in sustainability and governance.
4basebio enters research collaboration with eTheRNA
Cell and gene therapy intellectual property company 4basebio announced a strategic research collaboration between its wholly-owned subsidiary 4basebio Discovery and eTheRNA immunotherapies on Tuesday.
Avacta Group selects second pro-drug candidate
Clinical-stage biopharmaceutical company Avacta Group announced on Tuesday that the next ‘preCISION’ drug candidate, ‘AVA3996’, had been selected for preclinical development, with a view to a first-in-human phase one clinical trial from the second half of 2023.
Kape Technologies flags higher-than-expected full-year revenue
Digital security and privacy company Kape Technologies reported a “landmark” 2021 in a trading update on Tuesday, in which it achieved “significant” strategic progress and delivered a “record” financial performance.
Watkin Jones reports strengthening revenue, earnings
Rental housing developer Watkin Jones reported a 21. 5% improvement in revenue in its full-year results on Tuesday, to £430. 2m.
Alliance Pharma set to top underlying profit expectations
Alliance Pharma reported “strong” full-year growth in a trading update on Tuesday, with see-through revenue rising 23%, or 27% on a constant currency basis, to £169. 6m.
Hotel Chocolat Q2 revenues grow, FY seen 'marginally ahead' of expectations
Chocolatier Hotel Chocolat said on Tuesday that second-quarter total group revenues had increased 37% year-on-year and 63% when compared to the equivalent period in 2020.